Wai Chun Bio-Technology Clarifies FY2026 Gross Profit at HK$ 45.3 Million

PUBT · 6d ago
Wai Chun Bio-Technology Clarifies FY2026 Gross Profit at HK$ 45.3 Million
  • Wai Chun Bio-Technology corrected clerical errors in its annual results for the year ended June 30, 2026.
  • Gross profit was approximately HK$ 45.3 million, compared with HK$ 36 million a year earlier.
  • Gross margin increased to 11.2% from 9.5%, reflecting higher revenue and increased selling prices for small customers.
  • The share-capital correction covered HK$ 10 million of convertible bonds converted into 166,666,666 ordinary shares on April 27, 2026.
  • All other information in the annual results remained unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wai Chun Bio Technology Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12414515), on November 16, 2026, and is solely responsible for the information contained therein.